mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond

[Display omitted] mRNA-based vaccines are emerging as a promising alternative to standard cancer treatments and the conventional vaccines. Moreover, the FDA-approval of three nucleic acid based therapeutics (Onpattro, BNT162b2 and mRNA-1273) has further increased the interest and trust on this type...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2024-03, Vol.206, p.115190, Article 115190
Main Authors: Estapé Senti, Mariona, García del Valle, Lucía, Schiffelers, Raymond M.
Format: Article
Language:English
Subjects:
Cancer
Immunotherapy
Ionizable lipid
Lipid nanoparticles
mRNA
Nucleic acid
Peptide-based nanoparticles
Polymeric nanoparticles
RNA modifications
type I interferon responses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] mRNA-based vaccines are emerging as a promising alternative to standard cancer treatments and the conventional vaccines. Moreover, the FDA-approval of three nucleic acid based therapeutics (Onpattro, BNT162b2 and mRNA-1273) has further increased the interest and trust on this type of therapeutics. In order to achieve a significant therapeutic efficacy, the mRNA needs from a drug delivery system. In the last years, several delivery platforms have been explored, being the lipid nanoparticles (LNPs) the most well characterized and studied. A better understanding on how mRNA-based therapeutics operate (both the mRNA itself and the drug delivery system) will help to further improve their efficacy and safety. In this review, we will provide an overview of what mRNA cancer vaccines are and their mode of action and we will highlight the advantages and challenges of the different delivery platforms that are under investigation.
ISSN:0169-409X
1872-8294
1872-8294
DOI:10.1016/j.addr.2024.115190